Elyse Watkins, DHSc, PA-C, DFAAPA
Depression continues to rank among the most prevalent medical conditions globally. Despite the availability of numerous treatments for depression, there is still a large population that does not achieve remission through traditional antidepressants. Recent research has shown that injecting botulinum toxin type A (BTX-A) into the glabellar muscles significantly reduced depressive symptoms. Because BTX-A is widely used and has a well-established safety profile, medical providers should be aware of its promising benefits for depression. Additional research is required to ascertain the precise dosage of BTX-A, whether it be monotherapy or adjunct therapy, and to investigate the underlying mechanism.
Rohrer H. Botulinum Toxin Type A: A Novel Treatment for Depression. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2023; 5(2).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.